Public Safety, Crime Prevention Come Down to Numbers: Too Few Trying to Protect Many

NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) — NetworkNewsAudio – Knightscope Inc. announces the availability of a broadcast titled, “Technology Answers Call for Greater Public Safety, Crime Prevention.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/BdGjH

In 2019, the FBI reported about 2,110 property crimes and 379 violent crimes per 100,000 Americans, according to Pew Research. Leading the list of crimes were larceny/theft in the property crime category and aggravated assault in the violent crime category. Where the numbers actually fall in real life is a little more difficult to discern, considering the majority of crimes actually go unreported every year. One of the reasons cited for failing to report a crime is the belief that police can’t help. While disheartening, it is not a tremendous surprise considering that for years police forces have been reportedly understaffed amid a growing population.

As explained by Knightscope Inc. CEO William Santana Li, simple math illuminates the situation as a problem of numbers. There are one million law enforcement professionals and one million security personnel in the United States. Accounting for the number of hours these individuals can work on a daily and weekly basis, that equates to about 500,000 people at any one time trying to protect 328 million Americans across the entire country at any given moment.

About Knightscope Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. Learn more at www.Knightscope.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only).

For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website, applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork



Loop Media, Inc. Announces Partnership with Rad to Add Multiple New Channels Across Millions of PlayStations

Glendale, CA, Dec. 10, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Loop Media, Inc. (“Loop Media”), the first media company focused on fully integrated 360-degree engagement of music videos and other premium content for consumers and businesses (OTC: LPTV), today announced a partnership with Rad to bring 19 of Loop’s music video channels to the Rad platform. Rad (formerly known as Littlstar) was a launch partner on PlayStation 5 and recently introduced Watch Parties on Android TV for linear programming and live events.

Through the partnership, Loop’s content will be available on all devices that support the Rad app, collectively adding over a hundred million PS4’s, PS5’s, smart TVs and mobile devices to the Loop network. It also provides a foundation for technical innovation around content and dedicated communities, using Rad’s Watch Parties for streaming while people are stuck inside as a result of the COVID-19 pandemic. In addition, the content will be available to PlayStation VR users, where viewers can sit back in a personal theater away from the outside world.

Rad is currently featured on millions of PlayStation 4’s and a rapidly growing number of PS5’s. This collaboration came about when Rad held its Digital Mirage Festival, an EDM festival that saw a lot of traffic to the Loop channels. 

“This partnership with Rad across the Sony PlayStation-installed base is such a fantastic opportunity for Loop to have our content reach so many people who spend hours enjoying the entertainment they love,” said Jon Niermann, CEO and Co-Founder of Loop Media, Inc. “What I learned during my time with EA is that a gaming console like PlayStation is the most powerful entertainment machine people have in their homes. PlayStation has the largest distribution worldwide with hundreds of millions of machines, and that’s even prior to the huge current demand for the PS5, so it’s terrific for Loop to offer up our channels on these amazing consoles.”

“Music has been in our DNA since day one,” said Matt Collado, Co-Founder and Chief Content Officer of Rad. “We couldn’t be more excited to kick off our partnership with Loop by launching its incredible catalog of music videos.”

In addition to enjoying Loop music videos and other premium short-form content on Rad, audiences can enjoy the world’s largest music video library with the new Loop app for iPhone and Android. Businesses can also entertain their customers using the Loop Player, a small set top box that plays Loop Media’s growing collection of over 500,000 music, film, TV, sports and gaming videos. True to its name, Loop’s technology uniquely enables consumers to directly influence and control the Loop “in business” experience (in restaurants, bars, venues) via the same Loop consumer app, thereby linking the two. No other video app features that innovative power.

About Loop Media

Loop Media, Inc is the first media company focused on fully integrated 360-degree engagement of music videos and other premium short-form content by consumers and businesses. Loop improves the entire viewing experience for premium short-form content by focusing on venues and consumers in the evolving frontier of digital out-of-home, streamlining the public-to-private viewing experience. Loop’s growing library of over 500,000 short-form videos, including: music videos, film, game and TV trailers, viral videos, sports clips and atmospherics and travel videos can be viewed in many popular hospitality, dining, and retail venues; on leading branded media and entertainment sites; and on over-the-top TV platforms and CTV devices. To learn more about Loop products and applications, please visit us online at Loop.tv

About Rad

Rad is a community and streaming platform where you can stream the best in Free TV, Premium E-Sports, Gaming, Music, Comedy, Sports, Live events and VR experiences. Coordinate with your friends to watch TV together and join the conversation with live chat. Curate playlists to create your own TV channels, and share with family and friends. Stream live events, download virtual worlds and even collect points to customize your experience or get free content, products, and more. In addition, Rad offers the best video player on your PlayStation and PSVR to watch movies and videos you own along with RSS feeds and local network streaming via UPnP. The Rad app is available across devices, on PlayStation 4 and 5, PSVR, Android TV, mobile devices, and the web. Get more info at https://rad.live

Loop Media, Inc. Press:

Jon Lindsay Phillips
RLM PR
[email protected]
+1-646-828-8566



Kane Biotech Announces Launch of New Human Health OTC DermaKB™ Product Line

WINNIPEG, Manitoba, Dec. 10, 2020 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, is pleased to announce the commercial launch of its DermaKB™ shampoo, shampoo bar and scalp detoxifier as the first products in their new skin care line.

Derma KB products will be sold direct-to-consumer through Kane’s new online commerce site: www.dermakb.com.

“The launch of our DermaKB™ line is a major milestone for Kane as it marks our first commercialized products outside of Animal Health. Kane has developed a deep portfolio of anti-biofilm products, and our team is working hard to accelerate commercialization. Over the past year more than 4500 people have tested our DermaKB products and the results show high efficacy rates. I’m confident we can build these products into a commercial success,” commented Marc Edwards, CEO Kane Biotech.

The retail site will offer several shampoo products that contain Kane Biotech’s proprietary patented coactiv+™ technology. The products are formulated to provide an effective cleansing of the scalp, helping support the reduction of skin irritation and other symptoms associated with common skin conditions. DermaKB™ shampoo will be available on the website in a 1000ml bottle as well as in a four-pack of 45g shampoo bars. Additionally, a 500ml bottle scalp detoxifier will complement the product offering. The DermaKB™ product line is purposely unscented to avoid any further irritants for the consumer.

Kane’s Director of Marketing, Wendy Nachtigall, explains that “the DermaKB™ line is a high margin, premium line of shampoos and skin care products that contain no harsh chemicals for which we’ve chosen a direct-to-consumer approach. We intend to continue and further refine our consumer trials as part of our customer acquisition strategy. By leveraging social media, we have been able to entice consumers to try our products and the majority of people who do try our products have indicated both improvements in their conditions as well as their intent to purchase. We believe this can potentially be a very cost-effective customer acquisition strategy.”

“Over four thousand participants is a large consumer trial by anyone’s standard,” indicated Chief Scientific Officer Gordon Guay, PhD. “Prior to joining Kane, I spent 25 years as a research fellow at Proctor & Gamble where I had the opportunity to work on the development and validation of hundreds of new products. The results of this study clearly show there are a lot of people in discomfort and that our new shampoo line can bring relief to a substantial number of them.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information, please visit

www.kanebiotech.com

, or contact:

Marc Edwards Ray Dupuis Graham Farrell
Chief Executive Officer Chief Financial Officer Investor Relations
Kane Biotech Inc Kane Biotech Inc Harbor Access LLC

[email protected]

[email protected]
[email protected]
+1 (514) 910-6991 +1 (204) 298-2200 +1 (416) 842 9003

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.

COVID-19 Pandemic

Since December 31, 2019, the COVID-19 outbreak of the novel strain of coronavirus, SARS- CoV-2, has resulted in a widespread health crisis that has affected economies and financial markets around the world resulting in an economic downturn. The effects of this pandemic on the Company may include decreased customer demand, interruptions to supply chains, manufacturing activities and research and development programs and increased government regulations or interventions. The duration and impact of the COVID-19 outbreak is unknown at this time and it is not possible to reliably estimate the length and severity of these developments nor the impact of these developments on the financial results and condition of the Company in future periods.

Source: Kane Biotech Inc.



Stingray Launches the Stingray Music TV app on Videotron’s Helix TV

MONTREAL, Dec. 10, 2020 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY.A; RAY.B), a leading music, media, and technology company, today announced that its Stingray Music TV app has launched on Helix TV, Videotron’s entertainment platform. Starting today, Helix TV subscribers will have access to their favourite audio music channels like Stingray Hit List, Stingray Classic Rock or Stingray Hot Country through the brand new Stingray Music TV app.

Helix TV subscribers can also explore and enjoy an additional 2,000 professionally curated channels in over 100 genres including hip-hop, rock, pop, electronic, indie, country music and more! The Stingray Music TV app invites users to combine up to three filters amongst Activity, Mood, Theme, Genre and Era for a listening experience that’s uniquely theirs. Each combination returns a tailored selection of corresponding channels to choose from as well as additional suggestions they may also like.

In addition, the Stingray Music TV app will be accessible through Helix TV voice remote which will allow subscribers to say “Go to Stingray Music” to launch the app or “Play Stingray Pop Adult” to search for a specific channel with voice commands.

“We are thrilled to launch the Stingray Music TV app for the first time on a X1 platform with Videotron Helix, a key client, and long-lasting partner from our earliest days,” said Mathieu Péloquin, Senior Vice-President, Marketing and Communications of Stingray. “Our continued global success is partially due to leveraging the trust clients have placed in us and providing them with the highest level of service. This launch showcases the quality and diversity of Stingray’s growing product portfolio.”

About Stingray

Montreal-based Stingray (TSX: RAY.A; RAY.B) is a leading music, media, and technology company with over 1,200 employees worldwide. Stingray is a premium provider of curated direct-to-consumer and B2B services, including audio television channels, more than 100 radio stations, SVOD content, 4K UHD television channels, karaoke products, digital signage, in-store music, and music apps, which have been downloaded over 150 million times. Stingray reaches 400 million subscribers (or users) in 160 countries. For more information: www.stingray.com.

For more information, please contact:

Frédérique Gagnier

Public Relations Manager
Stingray
1 514-664-1244, ext. 2689
[email protected]



Leaf Group Announces Pricing of Public Offering of Common Stock

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Leaf Group Ltd. (NYSE: LEAF), a diversified consumer internet company, today announced the pricing of an underwritten registered public offering of 7,145,000 shares of its common stock at a price to the public of $4.20 per share.  In addition, Leaf Group granted the underwriters a 30-day option to purchase up to an additional 1,071,750 shares of its common stock. All shares of common stock sold in the offering are being sold by Leaf Group. Leaf Group expects to close the offering on December 14, 2020, subject to the satisfaction of customary closing conditions.

Leaf Group anticipates that the aggregate net proceeds from the offering will be approximately $27.8 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Leaf Group, but excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Leaf Group intends to use the net proceeds from the offering for working capital and general corporate purposes. Leaf Group may also use a portion of the net proceeds to acquire complementary businesses, products and technologies, although Leaf Group has no agreements, commitments or understandings to do so at this time.

Canaccord Genuity LLC is acting as sole book-running manager for the offering. BTIG, LLC is acting as co-manager for the offering.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-249476) that was declared effective by the U.S. Securities and Exchange Commission, or the SEC, on October 26, 2020. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on December 9, 2020. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and, when available, may be obtained by visiting the SEC’s website at www.sec.gov or by contacting Canaccord Genuity LLC, 99 High Street, 12th Floor, Boston, MA 02110, Attn: Syndicate Department, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About
Leaf Group

Leaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness and wellness (Well+Good, Livestrong.com and MyPlate App), and home, art and design (Saatchi Art, Society6 and Hunker).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding, but not limited to, the anticipated closing of the offering and Leaf Group’s expected uses of the proceeds from the offering. Forward-looking statements can be identified by the use of words such as “may,” “will,” “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue” or comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results or developments to differ materially from those indicated due to a number of factors affecting Leaf Group’s operations, markets, products and services. Leaf Group identifies the principal risks and uncertainties that may impact its performance in its public reports filed with the SEC, including the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition” sections of Leaf Group’s most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Forward-looking statements speak only as of the date on which they are made and Leaf Group assumes no obligation to update any forward-looking statements.

Investor Contact

Shawn Milne
SVP Corporate Finance and Investor Relations
310-656-6346
[email protected]  

 



InvestorBrandNetwork (IBN) Coverage Initiated for CannAssist International Corp.

NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) — via InvestorWire – CannAssist International Corp. (OTCQB: CNSC), a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

CannAssist is the owner of Xceptor Labs, an R&D and raw material manufacturing outfit leveraging its proprietary CiBiDinol technology to create CBD products that it believes have better absorption than currently marketed oil-based products. CiBiDinol is believed to provide CBD in a format that is more in line with the body’s natural bioactivity. It is specifically designed to address many critical issues with oil-soluble CBD molecules, including delivery, bioavailability and short shelf-life, while offering more predictable potency and enabling reduced dosage requirements.

As part of the Client Partner relationship with CannAssist, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for CannAssist International Corp.

“We are pleased to engage IBN to maximize our communication with existing and potential shareholders while refining our overall messaging and outreach,” states Mark Palumbo, CEO of CannAssist.

With 15+ years of experience assisting 500+ client partners improve communications within the investment community, and a sizable family of 50+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is uniquely positioned to provide CannAssist the solutions needed to reach a wide audience of investors, consumers, journalists and the general public.

“The cannabidiol market has been on fire since the 2018 Farm Bill was signed into law. In 2018, the global CBD market was valued at $4.6 billion, and it’s forecast to reach $23.6 billion by 2025, according to Grand View Research. CannAssist is uniquely positioned to capitalize on this market growth,” states Chris Johnson, Director of Client Solutions for IBN. “Based on current revenue from raw material sales, retail sales and the Xceptol brand’s international distribution, CannAssist expects to reach first-year sales of $5 million. We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it seeks to expand its product pipeline and achieve steady sales growth in the years ahead.”

To learn more about CannAssist, visit the company’s corporate newsroom profile at www.IBN.fm/CNSC

About CannAssist International Corp.

CannAssist produces and sells its cannabidiol (“CBD”) product, ‘CiBiDinol’, which is formulated based on a proprietary process developed by its founder, Mark Palumbo. CBD is a non-psychoactive compound found in hemp. CannAssist’s initial research and development work, aimed at enhancing the bioavailability of desired molecular structures, resulted in the creation of a line of CBD products, most notably its CBD product, CiBiDinol. CiBiDinol will be available in a line of consumable and topical products that the company believes will make enhanced CBD products more available and accessible to consumers.

For more information about the company, visit www.CannAssistInternational.com.

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of Client Partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]



Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major medical centers across the U.S.

A leading academic medical center in Northeast purchased the BVA-100® analyzer and has incorporated the BVA blood test into their inpatient treatment protocol for heart failure patients. A medical center in the Midwest purchased the BVA-100® analyzer for use in their outpatient heart failure clinic. In addition to these new purchases, three hospitals across the country have renewed their paid support agreements solidifying their commitment to the value of blood volume analysis in treating patients with volume derangements.

“Sales continue to excel despite the pandemic, further validating the clinical benefits of our technology in both inpatient and outpatient use,” said Michael Feldschuh, President and CEO of Daxor Corporation. “The BVA-100® blood test provides a simple, inexpensive, objective measurement of volume status and composition providing clinicians with actionable results to optimize fluid management and improve patient outcomes while driving substantial cost savings throughout the healthcare system.”

“We are encouraged by the continued growth and implementation of our market-leading, FDA-cleared diagnostic blood volume test as a new measure of care. Cost-benefit analysis shows BVA-guided care is 80 percent less costly than other therapies of equal patient benefit in our healthcare system while also demonstrating an impressive average life-extension of 2.32 quality-adjusted life years,” said Jean Oertel, Vice President of Commercialization and Customer Experience. “Daxor’s growing market share is driven by our expanded team of territory managers and clinical experts who are supporting our customers to achieve dramatic reductions in mortality rates and hospital readmissions.”

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
[email protected]



CEMATRIX Corporation Announces Appointment of Directors

CALGARY, Alberta, Dec. 10, 2020 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (the “Corporation”) is pleased to announce that, at the annual and special meeting of shareholders of the Corporation held on December 9, 2020 (the “AGM”), the following persons have been elected to serve on the board of directors of the Corporation: Jeffrey Kendrick, Robert L. Benson, Steve Bjornson, Patrick N. Breen, Dan Koyich and Minaz Lalani.

At the AGM, the Corporation received disinterested shareholder approval for the Corporation’s new Omnibus Equity Incentive Plan (the “Plan”) which replaces the existing rolling stock option plan of the Corporation.

The Plan includes a rolling stock option plan that provides for the grant of stock options (“Stock Options”) and a fixed restricted share unit plan that provides for the grant of restricted share units (“RSUs”). Under the Plan, these awards are available to employees, employees of a person or company which provides management services to the Corporation, consultants, and directors of the Corporation.

The maximum number of Common Shares which may be reserved and set aside for issuance upon the grant of stock options under the Plan will be 10% of the Corporation’s issued and outstanding share capital at the time of any grant, inclusive of a maximum of 6,467,923 Common Shares issuable pursuant to RSUs granted under the Plan.

ABOUT CEMATRIX

CEMATRIX is a rapidly growing, cash flow positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through recent acquisitions of Chicago based MixOnSite and Bellingham based Pacific International Grout, CEMATRIX is now North America’s largest Cellular Concrete company.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Jeff Kendrick – President and Chief Executive Officer
Phone: (403) 219-0484

Glen Akselrod – President, Bristol Capital
Phone: (905) 326 1888 ext 1
[email protected]

Jeff Walker – Vice President, The Howard Group
Phone: (888) 221-0915 or (403) 221-0915
[email protected]



Caladrius Biosciences to Webcast Live at Life Sciences Investor Forum

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com

BASKING RIDGE, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will present a live webcast at the Life Sciences Investor Forum on December 17th.

Date: Thursday, December 17, 2020
Time: 10:30-11:00 AM Eastern Time
Link:https://bit.ly/3mPSVkO

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.lifesciencesinvestorforum.com.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients. For more information on the company, please visit www.caladrius.com.

About Life Sciences Investor Forum

Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.

A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.



Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: [email protected]

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: [email protected]

3D Systems Announces Launch of Environmental, Social & Governance Initiative

ROCK HILL, S.C., Dec. 10, 2020 (GLOBE NEWSWIRE) — 3D Systems (NYSE:DDD) today announced the launch of its Environmental, Social & Governance (ESG) initiative – formalizing its commitment to taking action on global environmental, social, and health issues. This is a foundational element helping the company achieve its strategic purpose as the leaders in enabling additive manufacturing solutions for applications in growing markets that demand high-reliability products.

“3D Systems was founded on a spirit of innovation, and the work we do makes an impact on businesses, people’s lives and our environment,” said Dr. Jeffrey Graves, president, and CEO, 3D Systems. “With the launch of our ESG platform, we’re formalizing the commitment to the values and operating principles that have been part of the fabric of our company since its inception. We’re making an impact and proud to be part of a movement for change.”

The 3D Systems ESG initiative includes three areas which are core to the company’s daily operations:


  • Environmental Responsibility
    highlights the commitment to identifying and advocating for more sustainable options to reduce 3D Systems’ and its customers’ effect on the environment by replacing, optimizing, and creating processes that will help eliminate waste and reduce carbon emissions. Additive manufacturing plays a vital role in sustainability efforts through optimized part designs. For example, an airplane component can now weigh less yet perform more efficiently resulting in lowered fuel costs and environmental impact. Additionally, because additive manufacturing only uses the material needed to produce the final part, there is substantially less production waste than traditional manufacturing.

3D Systems has also undertaken efforts within the company to reduce its carbon footprint. In 2019, 3D Systems reduced its real estate assets by 10% resulting in lowering CO2 emissions by nearly 2.8 million pounds.1


  • Social Responsibility
    demonstrates an alliance with social causes and giving back to the communities where its employees live and work. 3D Systems’ efforts as the COVID-19 pandemic escalated showcased its desire to give back as the company issued a call to action to its customers and partners to share resources – producing and delivering much needed nasopharyngeal swabs, ventilator valves, and PPE. 

This month, the company also launched the 3D Systems Gives Back global giving campaign. This platform allows 3D Systems employees, families, and friends to donate to charities that are providing much-needed assistance for the COVID-19 response, as well as those advancing efforts that target social justice and diversity.


  • Responsible Practices & Governance
    whereby the company holds itself accountable to ethical and responsible practices and policies, including those related to employee health and safety. For 3D Systems, conducting its business on a highly ethical level is at the core of its business principles. The company’s Code of Conduct sets the ethical and legal standards of behavior and business practices that are required of all its employees and those of its subsidiaries globally. As a result, 3D Systems requires all board members and employees to complete training and certify compliance with its Code annually.

3D Systems’ employees are vital to the organizations’ success, and their health and safety is the company’s number one priority. As a result, 3D Systems not only continues to invest in safety standards and wellness policies and programs, but the company also continues to exceed industry-wide safety targets. For example, in 2019 3D Systems reported an incident rate of 0.72 which is 76% lower than the additive manufacturing industry standard of 3.0.2

For more information on the company’s Environmental, Social & Governance initiative, please visit the ESG page of 3D Systems’ website.

1. Estimate derived from EPA Tool Estimates Greenhouse Gas Emissions of Commercial Buildings.
2. OSHA (Occupational Safety and Health Administration) defines a recordable incident (i.e. recordable injury and illness) as 1) any work-related fatality, 2) any work-related injury or illness that results in loss of consciousness, days away from work, restricted work, or transfer to another job, 3) any work-related injury or illness requiring medical treatment beyond first aid, or 4) any work-related diagnosed case of cancer, chronic irreversible diseases, fractured or cracked bones or teeth, and punctured eardrums. Total Recordable Incident Rate (TRIR) = # of injuries & illnesses x 200,000/# of hours worked by all employees. 3D Systems executed 4,981,368 work hours resulting in a OSHA Recordable TRIR of 0.72. 

Forward-Looking Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems

More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading Additive Manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction – empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in Healthcare and Industrial markets such as Medical and Dental, Aerospace & Defense, Automotive, and Durable Goods. More information on the company is available at www.3dsystems.com.

Investor Contact: [email protected] 
Media Contact: [email protected]